Cytek Biosciences (CTKB) Treasury Shares (2021 - 2025)

Cytek Biosciences (CTKB) has 5 years of Treasury Shares data on file, last reported at $5.1 million in Q2 2025.

• For the quarter ending Q2 2025, Treasury Shares rose 1057.97% year-over-year to $5.1 million; the trailing twelve-month figure through Jun 2025 stood at $5.1 million (up 1057.97% YoY), and the FY2023 full-year result was $6.6 million, up 465.52% from the prior year.
• Treasury Shares for Q2 2025 stood at $5.1 million, down from $9.3 million in the prior quarter.
• Across five years, Treasury Shares topped out at $9.3 million in Q3 2024 and bottomed at $104876.0 in Q4 2021.
• The 5-year median for Treasury Shares is $1.2 million (2022), against an average of $3.0 million.
• The widest annual swing landed in 2024, when Treasury Shares slumped 85.63%; it then surged 1057.97% in 2025.
• A 5-year view of Treasury Shares shows it stood at $104876.0 in 2021, then soared by 1015.13% to $1.2 million in 2022, then soared by 465.52% to $6.6 million in 2023, then surged by 39.9% to $9.3 million in 2024, then tumbled by 44.39% to $5.1 million in 2025.
• The last three Treasury Shares figures came in at $5.1 million (Q2 2025), $9.3 million (Q3 2024), and $444319.0 (Q2 2024), per Business Quant data.

Peer Comparison